CXCL16-CXCR6 Chemokine-Axis Matching CAR-T Development Service

Creative Biolabs provides a CXCL16-CXCR6 Chemokine-Axis Matching CAR-T Development Service for Solid Tumor Targeting, engineered to improve T-cell trafficking, tumor infiltration, and functional persistence while reducing the risk of neurotoxicity. Through chemokine receptor integration, spatial homing optimization, and comprehensive mechanistic profiling, our platform enhances targeted accumulation and controlled immune activation within solid tumor environments.

Dual Role of the CXCL16-CXCR6 Axis

The CXCL16-CXCR6 chemokine axis represents a vital communication pathway in both immunological surveillance and disease pathology. CXCL16, which exists as both a membrane-bound adhesion molecule and a soluble chemoattractant, binds to its unique receptor, CXCR6, primarily expressed on T-cell subsets (effector and resident memory T cells). This axis plays a critical, often detrimental role in cancer: promoting chemoresistance and tumor invasiveness in numerous malignancies. Furthermore, it has a high-impact link to Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) severity in CAR T-cell therapy.

Service

Creative Biolabs offers a specialized service targeting the dualistic role of the CXCL16-CXCR6 axis in advanced cancer immunotherapies, specifically CAR T cells. This pathway is a critical determinant of both T-cell persistence and tumor infiltration (efficacy) and Central Nervous System (CNS) toxicity (safety). Our approach integrates trafficking enhancement with toxicity modulation, providing a complete solution for designing safer and more effective cellular therapies.

• Enhanced Solid Tumor Homing:

We engineer CAR T cells with optimized CXCR6 expression to leverage the high CXCL16 levels commonly present in solid tumor TMEs. This improves targeted T-cell trafficking and retention, directly addressing poor tumor infiltration.

• ICANS Risk Control:

We use in vitro and ex vivo models to evaluate neurotoxicity linked to the CXCL16–CXCR6 axis. By profiling CXCR6⁺ T-cell distribution and CXCL16 expression in CNS-associated tissues, we can refine CAR designs or recommend small-molecule modulators to reduce unwanted T-cell entry into the brain and lower ICANS risk.

• Chemoresistance Mitigation:

Our screening assays identify T-cell engineering strategies or molecular inhibitors that prevent tumors from exploiting CXCR6-mediated survival pathways to resist treatments such as docetaxel.

Discover How We Can Help - Request a Consultation.

Platform Technologies for Chemokine Axis Analysis

Creative Biolabs employs integrated technology platforms to fully characterize the CXCL16-CXCR6 axis and engineer optimal cell therapy candidates. Our services provide the necessary tools to predict, prevent, and promote T-cell function through chemokine receptor matching.

Work Process

The required starting materials include the car genetic sequence, primary human T-cells for initial testing, and relevant tumor cell lines for efficacy assessment.

Core Benefits

• Precise Targeting: Chemokine–receptor matching guides CAR-T cells directly to tumors.
• Enhanced Infiltration & Persistence: Overcomes TME barriers in solid tumors.
• Modular Design: Customizable to different tumor CXCL16 expression levels.
• Comprehensive Validation: End-to-end assessment from migration to cytotoxic activity.

Data Support

This study investigates the mechanisms of ICANS, a major side effect of CAR-T cell therapy. By analyzing patient samples, researchers discovered that a specific type of cytotoxic CAR-T cell, identified by the CXCR6 protein, is recruited into the central nervous system during ICANS. These cells interact with CXCL16-expressing myeloid cells in the brain.

Fig.1 Immunohistochemical staining for CXCL16 and CXCR6.¹

FAQs

Partner with Us

Creative Biolabs is a recognized leader in chemokine receptor engineering for adoptive cell therapy. Our unique advantage lies in our dual focus on enhanced efficacy and built-in safety, a necessity when dealing with the pleiotropic CXCL16-CXCR6 pathway. We combine published, cutting-edge mechanistic insights with proprietary high-throughput screening platforms. Connect with our team for details and project consultation.

Reference

1. Lu, I-Na et al. "The CXCL16/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy." Genome medicine vol. 17,1 71. 30 Jun. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.1186/s13073-025-01498-6